Literature DB >> 31858390

Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity.

Federica Coccia1, Moira Testa1, Gloria Guarisco1, Enea Bonci2, Claudio Di Cristofano3, Gianfranco Silecchia4, Frida Leonetti5, Amalia Gastaldelli6, Danila Capoccia1.   

Abstract

PURPOSE: In morbid obesity nonalcoholic fatty liver disease (NAFLD) is endemic. Aim of this study is to evaluate the diagnostic accuracy of the most common noninvasive methods for identify NAFLD and fibrosis in a cohort of morbid obese population.
METHODS: Ninety morbid obese patients undergoing bariatric surgery (BS) and intraoperative liver biopsy were evaluated preoperatively with Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) and serum biomarkers for steatosis and fibrosis and liver stiffness measurement (LSM) using acoustic radiation force impulse (ARFI) elastography. All nondiabetic patient (n = 77) underwent OGTT and calculation of Oral Glucose Insulin Sensitivity index (OGIS).
RESULTS: In the entire cohort prevalence of NAFLD was 77%, NASH 24%, moderate/severe steatosis 50%, and significant fibrosis 14%. New cut-offs were evaluated for all steatosis score assessed in this population. In all patients with moderate/severe steatosis HOMA IR was significantly greater than 3.5. ALT, GGT, Triglycerides, HOMA IR, and ARFI increased with fibrosis grade (p 0.03, p 0.008, p 0.04, p 0.05, respectively) and AST to Platelet ratio (APRI) was the only noninvasive fibrosis score significantly increased in significant fibrosis (p 0.04). A combination of 1/OGIS and VAI was able to discriminate NASH from simple steatosis (NAFL) (p 0.02).
CONCLUSIONS: In morbid obese subjects, we calculated new cut-offs of the most common steatosis indexes and found that a score based on insulin resistance (1/OGIS) and abdominal obesity (VAI) could represent a way to identify morbid obese subjects at risk of NASH.

Entities:  

Keywords:  Liver biopsy; NAFLD; Noninvasive exams; Obesity

Mesh:

Year:  2019        PMID: 31858390     DOI: 10.1007/s12020-019-02155-w

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  3 in total

1.  Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.

Authors:  Diana Barb; Enrico M Repetto; Michael E Stokes; Sudha S Shankar; Kenneth Cusi
Journal:  Obesity (Silver Spring)       Date:  2021-09-23       Impact factor: 9.298

2.  Deregulation of Secreted Frizzled-Related Protein 5 in Nonalcoholic Fatty Liver Disease Associated with Obesity.

Authors:  Laia Bertran; Marta Portillo-Carrasquer; Carmen Aguilar; José Antonio Porras; David Riesco; Salomé Martínez; Margarita Vives; Fàtima Sabench; Eva Gonzalez; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

Review 3.  The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis.

Authors:  Abdulrahman Ismaiel; Ayman Jaaouani; Daniel-Corneliu Leucuta; Stefan-Lucian Popa; Dan L Dumitrascu
Journal:  Biomedicines       Date:  2021-12-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.